URGN - Company ID 0001668243
The table below shows UroGen Pharma Ltd.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $109.97M | $90.04M | $92.90M | $104.03M | $124.92M | $219.97M |
| Short-term investments | $39.74M | $63.79M | $83.11M | $112.03M | $153.93M | $52.28M |
| Receivables | $55.41M | $19.70M | $19.65M | $19.64M | $22.80M | $17.41M |
| Inventory | $20.92M | $8.34M | $7.13M | $7.59M | $7.59M | $7.44M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $237.46M |
| $168.55M |
| $196.87M |
| $237.18M |
| $295.10M |
| $278.97M |
| Property, plant & equipment | $616.00K | $695.00K | $688.00K | $627.00K | $608.00K | $580.00K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $253.69M | $185.05M | $208.72M | $247.62M | $301.94M | $281.85M |
| Accounts payable | $17.21M | $10.28M | $13.56M | $14.57M | $5.56M | $8.32M |
| Total current liabilities | $50.63M | $42.24M | $47.55M | $42.00M | $32.79M | $34.22M |
| Long-term debt | $189.53M | $122.11M | $122.51M | $122.11M | $121.71M | $97.81M |
| Total liabilities | $377.94M | $300.45M | $302.09M | $294.08M | $276.43M | $251.53M |
| Retained earnings | -$983.29M | -$933.35M | -$900.00M | -$850.07M | -$768.71M | -$745.04M |
| Total equity | -$124.25M | -$115.41M | -$93.38M | -$46.46M | $25.52M | $30.31M |